When a paediatric indication is granted after completion of a deferred Paediatric Investigation Plan, a product needs to be made available on the market in all Member States where the adult product was already marketed, within the deadline as per Article 33 of Paediatric Regulation N. 1906/2006, i.e. within 2 years after the variation date.